Other Events ·
Evaxion A/S announced the expansion of its R&D pipeline with EVX-05, an AI-designed off-the-shelf therapeutic vaccine…
EVAXEvaxion A/S
Evaxion A/S announced the expansion of its R&D pipeline with EVX-05, an AI-designed off-the-shelf therapeutic vaccine for glioblastoma developed in collaboration with Duke University School of Medicine. The company discontinued the EVX-03 program as part of portfolio management and confirmed that costs for EVX-05 are covered by existing budgets, maintaining its cash runway into the second half of 2027. Evaxion is a clinical-stage TechBio company specializing in developing AI-powered cancer vaccines.